Company Qurient Co., Ltd.

Company Qurient Co., Ltd.

A115180

KR7115180002

Pharmaceuticals

Equities

A115180

KR7115180002

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Pharmaceuticals Wholesale

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Pharmaceuticals Wholesale

End-of-day quote Korea S.E. Other stock markets 23:00:00 25/06/2024 BST			5-day change	1st Jan Change
3,690 ^KRW	-0.14%		-0.54%	-20.99%

05-21	Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC	CI
05-17	Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI

Qurient Co., Ltd. is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company includes two programs: development phase programs and research phase programs. The development phase programs consist of Q203 which is drug-resistant tuberculosis treatment drug, Q301 which is atopic dermatitis treatment dug and Q701 which is used for treatment of drug resistant cancer and promotion anti-cancer immunotherapy. The research phase programs consist of 5 lipoxygenase (5LO) inhibit asthma medicines and cyclin dependent kinase 7 (CDK7) inhibit cancer drug.

KRW in Million	2022	Weight	2023	Weight	Delta
Medicine Wholesale and Retail 100.0 %	7,877	93.0 %	9,032	100.0 %	+14.66%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	8,469	100.0 %	9,032	100.0 %	+6.65%

Managers	Title	Age	Since
Ki-Yean Nam CEO	Chief Executive Officer	53	01/07/08
Peter Yu DFI	Director of Finance/CFO	51	31/07/22
Gi-Won Choi COO	Chief Operating Officer	52	-
Jae-Seung Kim BRD	Director/Board Member	56	-
Yoon-Su Kang AUD	Comptroller/Controller/Auditor	55	-

Members of the board	Title	Age	Since
Ki-Yean Nam CEO	Chief Executive Officer	53	01/07/08
Jae-Seung Kim BRD	Director/Board Member	56	-
Gi-Won Choi COO	Chief Operating Officer	52	-
Young-Mi Ji BRD	Director/Board Member	62	-
Tae-Sik Park BRD	Director/Board Member	64	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	483,652	0	2 ( 0.000414 %)	92.92 %
Stock B	0	101,400	0	0
Stock C	0	582,016	0	0
Stock D	1	29,813,589	27,703,392 ( 92.92 %)	5,389 ( 0.0181 %)

Name	Equities	%	Valuation
Donggu Bio Pharmaceutical Co. Ltd. 9.386 %	2,558,199	9.386 %	8 M ₩
Institut Pasteur Korea Research Foundation 3.966 %	1,080,875	3.966 %	3 M ₩
Woo-Ki Kim 2.604 %	709,640	2.604 %	2 M ₩
Mirae Asset Global Investments Co., Ltd. 2.483 %	676,703	2.483 %	2 M ₩
Quad Investment Management Co., Ltd. 1.723 %	469,495	1.723 %	1 M ₩
Ki-Yean Nam 0.9524 %	259,582	0.9524 %	793 999 ₩
Peter Yu 0.9317 %	253,946	0.9317 %	776 760 ₩
Jae-Seung Kim 0.6556 %	178,675	0.6556 %	546 524 ₩
Hyun-jin Lim 0.4084 %	111,319	0.4084 %	340 498 ₩
Gyeonggi Do 0.3971 %	108,244	0.3971 %	331 092 ₩

Name	Equities	%	Valuation
Ki-Yean Nam 16.98 %	193,461	16.98 %	591 751 ₩
Peter Yu 16.98 %	193,461	16.98 %	591 751 ₩
Eyun Yu Chang 16.98 %	193,461	16.98 %	591 751 ₩
Quad Investment Management Co., Ltd. 3.335 %	38,000	3.335 %	116 233 ₩

Qurient Co., Ltd.

C-dong 801, 242 Pangyo-ro Bundang-gu

13487, Seongnam-si

http://www.qurient.com

	1st Jan change	Capi.
QURIENT CO., LTD.	-20.99%	87.47M
MCKESSON CORPORATION	+29.50%	77.77B
CARDINAL HEALTH, INC.	+0.30%	24.62B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+14.70%	8.75B
SINOPHARM GROUP CO. LTD.	+0.73%	8.35B
HUADONG MEDICINE CO., LTD	-28.87%	7.1B
H. LUNDBECK A/S	+16.06%	5.25B
GALENICA AG	+1.58%	4.1B
EBOS GROUP LIMITED	-8.90%	3.8B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-7.62%	3.39B

Pharmaceuticals Wholesale

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Pharmaceuticals Wholesale